Datwyler invests in a new US drug delivery components plant
The automated facility for producing elastomer components for injectable drug delivery systems will meet the most stringent quality standards
Datwyler is putting more than CHF 100m (£80m) into building a new plant in the state of Delaware, US, which will be used to manufacture high-quality elastomer components for injectable drug delivery systems.
Construction work is likely to get under way before the end of 2016 and production is scheduled to start in the first half of 2018.
Once it is fully up and running, Datwyler’s new, highly automated plant in the US will provide jobs for around 120 employees.
Datwyler, which has been operating its own plant in the US since 1981, is a supplier to leading healthcare and pharmaceutical providers.
The new plant is to be designed, built and run in accordance with Datwyler’s latest 'FirstLine' standards.
This will make it possible to provide customers in the three key business regions of the US, Europe and Asia with locally produced “FirstLine” components in future.
The 'FirstLine' standards comprise a manufacturing concept for high-quality elastomer components based on ultra-modern cleanroom technology, automated production cells, fully automated camera inspection and a unique washing process.
The company says this innovative approach to manufacturing exceeds the most stringent quality standards of the European and US regulatory authorities and is certified to ISO 15378.